keyword
https://read.qxmd.com/read/38650495/dermoscopy-to-differentiate-clinically-similar-inflammatory-and-neoplastic-skin-lesions
#1
JOURNAL ARTICLE
Giulia Bazzacco, Iris Zalaudek, Enzo Errichetti
INTRODUCTION: Over the few last decades, dermoscopy has become an invaluable and popular imaging technique that complements the diagnostic armamentarium of dermatologists, being employed for both tumors and inflammatory diseases. Whereas distinction between neoplastic and inflammatory lesions is often straightforward based on clinical data, there are some scenarios that may be troublesome, e.g., solitary inflammatory lesions or tumors superimposed to a widespread inflammatory condition that may share macroscopic morphological findings...
April 2024: Italian journal of dermatology and venereology
https://read.qxmd.com/read/38631094/increased-cardiovascular-risks-and-mortality-in-prurigo-nodularis-a-global-cohort-study
#2
JOURNAL ARTICLE
Henning Olbrich, Khalaf Kridin, Gema Hernández, Henner Zirpel, Christian D Sadik, Patrick Terheyden, Diamant Thaçi, Ralf J Ludwig, Katharina Boch
BACKGROUND: Prurigo nodularis (PN) presents with intensely itchy hard nodules. Despite being limited to the skin, PN was noted to be associated with systemic diseases including diabetes and chronic renal failure. In previous smaller retrospective studies, several cardiac and vascular diseases were found more frequently in patients with PN. However, small cohort sizes, partially discrepant outcomes, missing data, and incomplete risk assessment limit these findings. METHODS: Electronic health records (EHR)s of 64,801 patients (59...
April 16, 2024: EBioMedicine
https://read.qxmd.com/read/38629497/efficacy-and-safety-of-nemolizumab-and-topical-corticosteroids-for-prurigo-nodularis-results-from-a-randomised-double-blind-placebo-controlled-phase-ii-iii-clinical-study-in-patients-aged-%C3%A2-13-years
#3
JOURNAL ARTICLE
Hiroo Yokozeki, Hiroyuki Murota, Takayo Matsumura, Hiroshi Komazaki
BACKGROUND: Prurigo nodularis, a chronic inflammatory skin condition, adversely affects the quality of life of affected individuals. Current treatment options for prurigo nodularis in Japan are limited. OBJECTIVES: To evaluate the optimal dose, efficacy, and safety of long-term treatment with nemolizumab in patients with prurigo nodularis in Japan. METHODS: In a 16-week, double-blind, phase II/III study, patients aged ≥13 years with prurigo nodularis were randomly assigned (1:1:1) to nemolizumab 30 mg, 60 mg, or placebo groups, with concomitant topical corticosteroids, every 4 weeks...
April 17, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38619203/dupilumab-effectiveness-in-a-case-of-prurigo-nodularis-and-severe-recalcitrant-hidradenitis-suppurativa
#4
JOURNAL ARTICLE
Raffaele D Caposiena Caro, Giulia Bazzacco, Enrico Zelin, Vanessa Mazzoletti, Marina Agozzino, Diego Signoretto, Nicola DI Meo, Iris Zalaudek
No abstract text is available yet for this article.
April 12, 2024: Italian journal of dermatology and venereology
https://read.qxmd.com/read/38616037/hiv-related-exclusion-criteria-in-atopic-dermatitis-and-prurigo-nodularis-clinical-trials
#5
JOURNAL ARTICLE
Rebecca Leibowitz, Anna Fischer, Lauren F Collins, Ron J Feldman, Howa Yeung
No abstract text is available yet for this article.
April 12, 2024: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/38582943/comprehensive-plasma-cytokine-and-chemokine-profiling-in-prurigo-nodularis-reveals-endotypes-in-type-2-inflammation
#6
JOURNAL ARTICLE
Hannah L Cornman, Jaya Manjunath, Sriya V Reddy, Jackson Adams, Ahmad Rajeh, Christeen Samuel, Aaron Bao, Ryan Zhao, Emily Z Ma, Jason Shumsky, Thomas W Pritchard, Brenda Umenita Imo, Alexander L Kollhoff, Kevin K Lee, Weiying Lu, Selina Yossef, Madan M Kwatra, Shawn G Kwatra
Prurigo nodularis (PN) is a chronic inflammatory skin disease that is associated with variability in peripheral blood eosinophil levels and response to T-helper 2 targeted therapies (Th2). Our objective was to determine whether circulating immune profiles with respect to type 2 inflammation differ by race and peripheral blood eosinophil count. Plasma from 56 PN patients and 13 matched healthy controls was assayed for 54 inflammatory biomarkers. We compared biomarker levels between PN and HCs, among PN patients based on absolute eosinophil count, and across racial groups in PN...
April 6, 2024: Scientific Reports
https://read.qxmd.com/read/38581104/deciphering-the-enigma-of-itch-sensation-insights-and-impact-from-a-readability-study
#7
JOURNAL ARTICLE
Tomasz Skrzypczak, Anna Skrzypczak, Jacek C Szepietowski
BACKGROUND: Itch terminology is ambiguous. How itch was described in online materials and how terminology influenced the readability of these materials was previously unknown. MATERIALS AND METHODS: Two groups of search terms, itch and prurigo, were translated into five of the most prevalent European Union (EU) languages. The itch group consisted of "itch" and "pruritus." The prurigo group consisted of "prurigo," "prurigo nodularis," and "chronic prurigo". Then, a search of the terms in each language was queried in the Google search engine in the private mode of the Internet browser...
April 5, 2024: International Journal of Dermatology
https://read.qxmd.com/read/38563058/validation-of-a-scoring-algorithm-for-the-clinician-reported-outcome-tool-prurigo-activity-and-severity-pas-based-on-clinical-studies-of-dupilumab-in-adults-with-prurigo-nodularis
#8
JOURNAL ARTICLE
Claudia Zeidler, Sonja Stander, Stephanie Rhoten, Samantha Wratten, Dian Zhang, Jerome Msihid, Ella Brookes, Ryan Thomas, Donia Bahloul
BACKGROUND: Prurigo nodularis (PN) also known as chronic prurigo, is a chronic inflammatory skin disease characterized by intensely itchy nodules/lesions which occur due to intensive scratching. PN management is, in part, based on clinician evaluations of PN lesions, which can be supported by clinician-reported outcomes (ClinRO) such as the Prurigo Activity and Severity (PAS) instrument. A 5-item version of PAS was included in recent phase-3 dupilumab PN trials (PRIME [NCT04183335]/PRIME2 [NCT04202679])...
April 2, 2024: Journal of the European Academy of Dermatology and Venereology: JEADV
https://read.qxmd.com/read/38533565/comorbidities-of-prurigo-nodularis-in-chinese-patients-a-multicenter-retrospective-study
#9
JOURNAL ARTICLE
Mengting Yin, Weilong Zhong, Keren Zhou, Xia Dou
No abstract text is available yet for this article.
March 26, 2024: Chinese Medical Journal
https://read.qxmd.com/read/38522569/spatial-mass-cytometry-based-single-cell-imaging-reveals-a-disrupted-epithelial-immune-axis-in-prurigo-nodularis
#10
JOURNAL ARTICLE
Jay Patel, Junwen Deng, Anusha Kambala, Kevin K Lee, Hannah L Cornman, Varsha Parthasarathy, Thomas Pritchard, Shihua Chen, Alexei G Hernandez, Sarah Shin, Olusola O Oladipo, Madan M Kwatra, Won Jin Ho, Shawn G Kwatra
Prurigo nodularis (PN) is a chronic, inflammatory skin condition that disproportionately affects African Americans and features intensely pruritic, hyperkeratotic nodules on the extremities and trunk. PN is understudied compared to other inflammatory skin diseases, with the spatial organization of the cutaneous infiltrate in PN yet to be characterized. In this work, we employ spatial imaging mass cytometry to visualize prurigo nodularis lesional skin inflammation and architecture with single cell resolution through an unbiased machine learning approach...
March 22, 2024: Journal of Investigative Dermatology
https://read.qxmd.com/read/38507442/a-case-of-bullous-pemphigoid-following-administration-of-anti-il-31-receptor-a-antibody
#11
JOURNAL ARTICLE
Ryosuke Masuyuki, Emi Sato, Shinichi Imafuku
Bullous pemphigoid (BP), an autoimmune bullous dermatosis, occurs predominantly in older individuals. Nemolizumab, a humanized monoclonal antibody against the interleukin (IL)-31 receptor A, is used to treat severe atopic dermatitis (AD) in Japan. However, it can cause several adverse events, such as exacerbation of AD, erythema, and eosinophilia. Herein, we describe a case of prurigo-type AD developing BP after nemolizumab administration. A 62-year-old man with prurigo-type AD and asthma presented with serious, refractory itching...
March 20, 2024: Journal of Dermatology
https://read.qxmd.com/read/38494622/clinical-and-temporal-characteristics-of-malignancy-associated-prurigo-nodularis-a-systematic-review
#12
JOURNAL ARTICLE
Maxwell Green, Laura Williams, Drew Kuraitis
No abstract text is available yet for this article.
2024: Skinmed
https://read.qxmd.com/read/38479690/angiomatosis-prurigiforme-una-nueva-entidad-propuesta-para-la-proliferaci%C3%A3-n-angiomatoide-d%C3%A3-rmica-prominente-subyacente-a-los-cambios-epid%C3%A3-rmicos-de-prurigo-nodularis-liquen-simple-cr%C3%A3-nico
#13
R Albero González, D Rizo Potau, L Alós Hernández, P Castillo Fernández, A García Herrera
Vascular hyperplasia is a common finding in prurigo nodularis/lichen simplex chronicus (LSC). The term prurigiform angiomatosis was recently proposed to describe a histologic pattern characterized by prominent vascular hyperplasia in patients with LSC. The aim of this study was to identify cases of LSC with this pattern and analyze associations with clinical and pathologic features and disease course. We reviewed 54 cases of histologically confirmed LSC and detected findings consistent with prurigiform angiomatosis in 10 (18...
March 11, 2024: Actas Dermo-sifiliográficas
https://read.qxmd.com/read/38460679/learnings-from-nemolizumab-a-promising-therapy-for-prurigo-nodularis
#14
EDITORIAL
Brian S Kim
No abstract text is available yet for this article.
March 7, 2024: Journal of Allergy and Clinical Immunology
https://read.qxmd.com/read/38455862/successful-treatment-of-refractory-prurigo-nodularis-with-abrocitinib
#15
Fang Sun, Zhenzhen Wu
Prurigo nodularis is frequently difficult to manage with conventional therapy. Given the pathogenesis and refractory nature, we demonstrate a case in which inhibition of JAK-STAT signaling may significantly improve prurigo nodularis. Based on the results, we would like to draw a conclusion that abrocitinib as an inhibitor of Jak is a promising choice for the treatment of prurigo nodularis.
March 2024: Clinical Case Reports
https://read.qxmd.com/read/38397136/dysregulation-of-the-skin-liver-axis-in-prurigo-nodularis-an-integrated-genomic-transcriptomic-and-population-based-analysis
#16
JOURNAL ARTICLE
Melika Marani, Vrinda Madan, Thomas K Le, Junwen Deng, Kevin K Lee, Emily Z Ma, Shawn G Kwatra
Pruritus has long been linked to hepatic dysfunction; however, there are limited data characterizing the association between liver disease and prurigo nodularis (PN), a chronic inflammatory skin disease featuring severe pruritis. We thus conducted a cross-sectional analysis of hepatic comorbidities in PN patients using TriNetX, a large global health research network. This analysis revealed that PN patients had a higher risk ( p < 0.001) of developing liver cirrhosis, acute and subacute hepatic failure, inflammatory liver disease, chronic hepatitis, nonalcoholic steatohepatitis, portal hypertension, fatty liver, chronic passive congestion of the liver, and hepatocellular carcinoma compared with healthy controls...
January 23, 2024: Genes
https://read.qxmd.com/read/38394406/evaluation-of-the-histopathological-spectrum-of-skin-biopsies-in-patients-with-chronic-kidney-disease-a-single-center-experience
#17
JOURNAL ARTICLE
Amany A Fathaddin
BACKGROUND AND AIM: Patients with chronic kidney disease (CKD), particularly those with end-stage renal disease (ESRD), frequently experience skin problems. Here, we present and discuss the histopathology results of skin biopsies performed on renal patients at our facility. MATERIALS AND METHODS: We retrospectively reviewed all histopathological reports and slides of skin biopsies taken from CKD patients for the last 5 years at the Pathology Department of King Saud University Medical City, King Saud University in Riyadh...
November 9, 2023: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/38345154/prurigo-nodularis-new-insights-into-pathogenesis-and-novel-therapeutics
#18
JOURNAL ARTICLE
Viviane Liao, Hannah L Cornman, Emily Ma, Shawn G Kwatra
Prurigo nodularis (PN) is an inflammatory skin condition characterized by intensely pruritic nodules on the skin. PN patients suffer from an intractable itch-scratch cycle leading to impaired sleep, psychosocial distress, and a significant disruption in quality of life. The pathogenesis of PN is associated with immune and neural dysregulation, mediated by inflammatory cytokines (such as IL-4, -13, -17, -22, and -31) and neuropeptides (such as substance P and calcitonin gene-related peptide). There is a role for type 2 inflammation in PN in addition to Th17 and Th22-mediated inflammation...
February 12, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38337572/dupilumab-for-treatment-of-prurigo-nodularis-real-life-effectiveness-for-up-to-84-weeks
#19
JOURNAL ARTICLE
Claudia Paganini, Marina Talamonti, Virginia Maffei, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo
(1) Background: Prurigo nodularis (PN) is a persistent and inflammatory dermatological condition characterized by chronic itching and the formation of hardened nodules, significantly impacting the affected individuals' quality of life and psychological well-being. The management of PN poses challenges due to the limited efficacy and undesirable side effects associated with current interventions. (2) Methods: This article examines sixteen patients affected by PN treated with dupilumab, a fully human monoclonal antibody targeting interleukin IL-4 and IL-13 signaling...
February 2, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38332383/a-systematic-review-of-interleukin-31-inhibitors-in-the-treatment-of-prurigo-nodularis
#20
REVIEW
Mohammad Ali Nilforoushzadeh, Nazila Heidari, Yekta Ghane, Amirhossein Heidari, Arman Hajikarim-Hamedani, SeyedAyin Hosseini, Fariba Jaffary, Minou Najar Nobari, Pegah Tavakolzadeh, Niloufar Najar Nobari
BACKGROUND: Prurigo nodularis (PN) is a neuroimmunological skin disease. Severe itching is the most challenging symptom which affects patients' quality of life. T helper 2-derived cytokines, such as interleukin-31 and oncostatin M (OSM), play a crucial role in PN pathogenesis. Nemolizumab and vixarelimab are two biologics acting as IL-31 inhibitors. Vixarelimab also suppresses the OSM activity. This systematic review evaluates the efficacy and safety of nemolizumab and vixarelimab in PN management...
February 8, 2024: Inflammopharmacology
keyword
keyword
12902
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.